Table 1.
Patient baseline demographics and screening lung function (intent-to-treat population)
| Placebo (n = 58) | FF/VI 100/25 (n = 56) | FF/VI 200/25 (n = 56) | Prednisolone (n = 15) | Total (N = 185) | |
|---|---|---|---|---|---|
| Age, years | 36.1 (15.42) | 34.4 (15.63) | 34.0 (13.74) | 37.5 (14.19) | 35.1 (14.82) |
| Age <18 years, n (%) | 5 (9) | 5 (9) | 7 (13) | 1 (7) | 18 (10) |
| Female gender, n (%) | 27 (47) | 31 (55) | 23 (41) | 6 (40) | 87 (47) |
| Screening lung function | |||||
| Pre-bronchodilator FEV1 (L) | 2.78 (0.73) | 2.90 (0.83) | 2.92 (0.76) | 3.03 (1.02) | 2.88 (0.79) |
| Pre-bronchodilator % predicted FEV1 | 77.0 (11.88) | 79.9 (12.58) | 77.5 (13.22) | 78.6 (13.17) | 78.2 (12.57) |
Values are mean (SD) unless otherwise stated.
FEV1, forced expiratory volume in 1 s; FF, fluticasone furoate; SD, standard deviation; VI, vilanterol.